NCT00014170View on ClinicalTrials.gov

Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

July 31, 2003

Conditions
Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
Interventions
DRUG

gefitinib

Given orally

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

questionnaire administration

Ancillary studies

PROCEDURE

quality-of-life assessment

Ancillary studies

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00014170 - Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter